GlobeNewswire Inc.··Not SpecifiedEyePoint Sets March 4 Earnings Call as Pipeline Advances Toward Key Milestones
EyePoint will report 2025 results March 4, highlighting pipeline progress. Lead drug DURAVYU™ advances toward Phase 3 trials for retinal diseases with key data expected mid-2026.
EYPTbiopharmaceuticalretinal diseases